TURNER DANIEL K III 4
4 · Transcept Pharmaceuticals Inc · Filed Mar 30, 2011
Insider Transaction Report
Form 4
TURNER DANIEL K III
Director
Transactions
- Sale
Common Stock
2011-03-29$8.17/sh−65,000$530,940→ 569,361 total(indirect: See footnote) - Sale
Common Stock
2011-03-29$8.17/sh−65,000$530,940→ 471,749 total(indirect: See footnote)
Holdings
- 58,178(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $8.10 to $8.57 per share. Upon request of the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F2]The reported securites are owned directly by Montreux Equity Partners II SBIC, L.P. ("MEP II") and may be deemed to be beneficially owned indirectly by Montreux Equity Management II SBIC, LLC ("MEM II"), as a general partner of MEP II. The reporting person is a managing member of MEM II and disclaims any beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]The reported securites are owned directly by Montreux Equity Partners III SBIC, L.P. ("MEP III") and may be deemed to be beneficially owned indirectly by Montreux Equity Management III SBIC, LLC ("MEM III"), as a general partner of MEP III. The reporting person is a managing member of MEM III and disclaims any beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F4]The reported securites are owned directly by Montreux IV Associates, LLC ("Montreux IV") and may be deemed to be beneficially owned indirectly by Montreux Equity Management IV LLC ("MEM IV"), as a general partner of Montreux IV. The reporting person is a managing member of MEM IV and disclaims any beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.